Related Experiment Videos
Perspectives on the development of a molecularly targeted agent
1Leukemia Center, Oregon Health & Science University Cancer Institute, 3181 SW Sam Jackson Park Road, Portland 97201, USA. drukerb@ohsu.edu
Cancer Cell
|June 28, 2002
Summary
STI571, also known as imatinib mesylate, is a targeted therapy for chronic myelogenous leukemia. It works by inhibiting the Bcr-Abl abnormality, with ongoing research into resistance and broader applications.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Chronic myelogenous leukemia (CML) is characterized by the Bcr-Abl fusion protein.
- Targeted therapies offer a new approach to cancer treatment.
Purpose of the Study:
- To review the development of STI571 (imatinib mesylate) for CML.
- To explore Bcr-Abl as a therapeutic target.
- To discuss clinical trial considerations and resistance mechanisms.
Main Methods:
- Review of scientific literature on STI571 development.
- Analysis of Bcr-Abl's role in CML pathogenesis.
- Examination of clinical trial data and resistance studies.
Main Results:
- STI571 (imatinib mesylate) effectively targets the Bcr-Abl abnormality in CML.
- Clinical trials established optimal dosing and patient selection.
- Mechanisms of resistance to STI571 have been identified.
Conclusions:
- STI571 represents a successful model for rational drug design in oncology.
- The paradigm of molecularly targeted therapy is being explored for other cancers.
- Further research is needed to overcome resistance and expand therapeutic applications.